GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (
NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Deadline Approaching: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithLaw Offices of Howard G. Smith reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”).
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines – GOSSNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky"We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session.
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to file a lead plaintiff motion.
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (
NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Law Offices of Frank R. Cruz Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to file a lead plaintiff motion.
Law Offices of Howard G. Smith Encourages Gossamer Bio, Inc. (GOSS) Shareholders To Inquire About Securities Fraud Class ActionLaw Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to file a lead plaintiff motion.
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law FirmGlancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) investors concerning the Company’s possible violations of the federal securities laws.
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationLaw Offices of Howard G. Smith announces an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) investors concerning the Company’s possible violations of federal securities laws.
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, April 03, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (
NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – GOSS
The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (
NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. CruzThe Law Offices of Frank R. Cruz announces an investigation of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS) on behalf of investors concerning the Company’s possible violations of federal securities laws.
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (
NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (
NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSSNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSNEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (
NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (
NASDAQ: GOSS) for violations of the securities laws.
